{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:39:22Z","timestamp":1791031162170,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The development of alloantibodies against von Willebrand factor (VWF) represents a rare but serious complication of treatment of von Willebrand disease (VWD), occurring in \u223c5% to 10% of type 3 VWD patients. Affected patients can present with a range of symptoms, including lack or loss of hemostatic response to infused VWF concentrates up to anaphylactic reactions in rare cases. It is classically reported in multitransfused patients and occurs most frequently in patients with partial or complete VWF gene deletions. A positive family history of anti-VWF antibodies also appears to be a risk factor. There is a lack of standardization of laboratory methods for antibody identification and characterization. Issues of variability in laboratory approaches as well as the rarity of the complication act as a barrier to future studies. Recombinant factor VIII as well as bypassing agents and immune tolerance have been reported as effective treatments; however, aside from case reports, little exists in the literature to guide management. The imminent clinical availability of recombinant VWF has prompted a resurgence of interest in this area. Additional study is warranted to address the deficiencies in our understanding of this treatment complication.<\/jats:p>","DOI":"10.1182\/blood-2012-10-462085","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T17:39:36Z","timestamp":1357666776000},"page":"636-640","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":106,"title":["Alloantibodies in von Willebrand disease"],"prefix":"10.1182","volume":"122","author":[{"given":"Paula D.","family":"James","sequence":"first","affiliation":[{"name":"Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen\u2019s University, Kingston, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier M.","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Scientific Direction, Istituto Di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Maggiore Policlinico Hospital Foundation, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111816452111600_B1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u2019s disease.","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"issue":"6","key":"2019111816452111600_B2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0022-3476(05)80384-1","article-title":"Prevalence of von Willebrand disease in children: a multiethnic study.","volume":"123","author":"Werner","year":"1993","journal-title":"J Pediatr"},{"issue":"1","key":"2019111816452111600_B3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice.","volume":"8","author":"Bowman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111816452111600_B4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1365-2516.1999.00302.x","article-title":"Hereditary pseudohaemophilia.","volume":"5","author":"Von Willebrand","year":"1999","journal-title":"Haemophilia"},{"issue":"10","key":"2019111816452111600_B5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019111816452111600_B6","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1073\/pnas.71.8.2937","article-title":"Nature of von Willebrand factor: a new assay and a specific inhibitor.","volume":"71","author":"Sarji","year":"1974","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111816452111600_B7","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1073\/pnas.72.10.4167","article-title":"Antibody nature of circulating inhibitor of plasma von Willebrand factor.","volume":"72","author":"Stratton","year":"1975","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111816452111600_B8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0049-3848(76)90209-7","article-title":"On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand\u2019s disease.","volume":"9","author":"Egberg","year":"1976","journal-title":"Thromb Res"},{"issue":"5564","key":"2019111816452111600_B9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/262141a0","article-title":"Precipitating antibodies in von Willebrand\u2019s disease.","volume":"262","author":"Mannucci","year":"1976","journal-title":"Nature"},{"issue":"5","key":"2019111816452111600_B10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.1987.tb01458.x","article-title":"Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor.","volume":"39","author":"Mannucci","year":"1987","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111816452111600_B11","first-page":"348","article-title":"Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.","volume":"125","author":"Bergamaschini","year":"1995","journal-title":"J Lab Clin Med"},{"key":"2019111816452111600_B12","first-page":"109","article-title":"Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand\u2019s disease.","volume":"150","author":"Mannucci","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"2019111816452111600_B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4613-0331-2_7","article-title":"Antibodies to von Willebrand factor in von Willebrand disease.","volume":"386","author":"Mannucci","year":"1995","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2019111816452111600_B14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2516.2008.01679.x","article-title":"Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.","volume":"14","author":"Iorio","year":"2008","journal-title":"Haemophilia"},{"issue":"7","key":"2019111816452111600_B15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors.","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"2019111816452111600_B16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2516.2004.00993.x","article-title":"Inhibitors in haemophilia: clinical aspects.","volume":"10","author":"Dimichele","year":"2004","journal-title":"Haemophilia"},{"issue":"6","key":"2019111816452111600_B17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison.","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111816452111600_B18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0002-9343(80)80026-X","article-title":"Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia.","volume":"69","author":"Helmer","year":"1980","journal-title":"Am J Med"},{"issue":"6","key":"2019111816452111600_B19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1537-2995.1988.28689059042.x","article-title":"Anaphylactic reaction to purified anti-hemophilic factor concentrate.","volume":"28","author":"Bove","year":"1988","journal-title":"Transfusion"},{"issue":"4","key":"2019111816452111600_B20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1537-2995.1996.36496226153.x","article-title":"Anaphylaxis after treatment with recombinant factor VIII.","volume":"36","author":"Shopnick","year":"1996","journal-title":"Transfusion"},{"issue":"3","key":"2019111816452111600_B21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0925-5710(95)00405-H","article-title":"Retrospective study of inhibitor formation in Japanese hemophiliacs.","volume":"62","author":"Kamiya","year":"1995","journal-title":"Int J Hematol"},{"issue":"6","key":"2019111816452111600_B22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1055\/s-0038-1648507","article-title":"Prevalence of inhibitors in a population of 3435 hemophilia patients in France.","volume":"67","author":"Sultan","year":"1992","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111816452111600_B23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MBC.0b013e328329f265","article-title":"Anaphylaxis in patients with congenital bleeding disorders and inhibitors.","volume":"20","author":"Franchini","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2019111816452111600_B24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.1999.t01-1-00303.x","article-title":"Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.","volume":"5","author":"Thorland","year":"1999","journal-title":"Haemophilia"},{"issue":"4","key":"2019111816452111600_B25","first-page":"850","article-title":"Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I.","volume":"51","author":"Zhang","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2019111816452111600_B26","first-page":"60","article-title":"Familial incidence of precipitating antibodies in von Willebrand\u2019s disease: a study of four cases.","volume":"94","author":"Ruggeri","year":"1979","journal-title":"J Lab Clin Med"},{"issue":"5","key":"2019111816452111600_B27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI112974","article-title":"Gene deletions correlate with the development of alloantibodies in von Willebrand disease.","volume":"79","author":"Shelton-Inloes","year":"1987","journal-title":"J Clin Invest"},{"issue":"5-6","key":"2019111816452111600_B28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0049-3848(79)90229-9","article-title":"High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand\u2019s disease and inhibitor.","volume":"16","author":"Bloom","year":"1979","journal-title":"Thromb Res"},{"issue":"2-3","key":"2019111816452111600_B29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0049-3848(79)90257-3","article-title":"Inhibition of Willebrand factor in von Willebrand disease.","volume":"14","author":"Maragall","year":"1979","journal-title":"Thromb Res"},{"issue":"3","key":"2019111816452111600_B30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1079-9796(03)00033-0","article-title":"Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.","volume":"30","author":"Baronciani","year":"2003","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"2019111816452111600_B31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1538-7836.2008.03107.x","article-title":"An Alu-mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary.","volume":"6","author":"Mohl","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111816452111600_B32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1538-7836.2011.04250.x","article-title":"Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population.","volume":"9","author":"Mohl","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"Suppl 6","key":"2019111816452111600_B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2012.02925.x","article-title":"von Willebrand\u2019s disease: a report from a meeting in the \u00c5land islands.","volume":"18","author":"Berntorp","year":"2012","journal-title":"Haemophilia"},{"issue":"10","key":"2019111816452111600_B34","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.V84.10.3378.3378","article-title":"Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.","volume":"84","author":"van Genderen","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2019111816452111600_B35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","article-title":"Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.","volume":"6","author":"Tiede","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"1-2","key":"2019111816452111600_B36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0022-1759(96)00209-8","article-title":"vWf inhibitor detection by competitive ELISA.","volume":"200","author":"Stewart","year":"1997","journal-title":"J Immunol Methods"},{"issue":"3","key":"2019111816452111600_B37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2516.2003.00750.x","article-title":"A new ELISA assay for diagnosis of acquired von Willebrand syndrome.","volume":"9","author":"Siaka","year":"2003","journal-title":"Haemophilia"},{"issue":"2","key":"2019111816452111600_B38","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0037-1613799","article-title":"Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.","volume":"83","author":"Tout","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111816452111600_B39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood.V72.1.116.116","article-title":"Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease.","volume":"72","author":"L\u00f3pez-Fern\u00e1ndez","year":"1988","journal-title":"Blood"},{"issue":"3","key":"2019111816452111600_B40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s002770050323","article-title":"Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.","volume":"75","author":"Batlle","year":"1997","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111816452111600_B41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand disease: results from the von Willebrand's Disease Prophylaxis Network (VWD PN).","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"issue":"4","key":"2019111816452111600_B42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1160\/TH10-09-0616","article-title":"Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study.","volume":"105","author":"Halimeh","year":"2011","journal-title":"Thromb Haemost"},{"issue":"3","key":"2019111816452111600_B43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2516.2008.01668.x","article-title":"Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report.","volume":"14","author":"Franchini","year":"2008","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"2019111816452111600_B44","first-page":"150","article-title":"Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand\u2019s disease and an inhibitor against von Willebrand factor.","volume":"26","author":"Ciavarella","year":"1996","journal-title":"Haemostasis"},{"issue":"3","key":"2019111816452111600_B45","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1111\/j.1365-2516.2012.02799.x","article-title":"The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor.","volume":"18","author":"Pergantou","year":"2012","journal-title":"Haemophilia"},{"issue":"7","key":"2019111816452111600_B46","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1073\/pnas.92.7.2428","article-title":"Platelet von Willebrand factor in inherited and acquired bleeding disorders.","volume":"92","author":"Mannucci","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111816452111600_B47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0049-3848(77)90065-2","article-title":"Factor VIII related antigen in platelets of patients with Von Willebrand\u2019s disease.","volume":"11","author":"Sultan","year":"1977","journal-title":"Thromb Res"},{"key":"2019111816452111600_B48"},{"issue":"8","key":"2019111816452111600_B49","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1073\/pnas.85.8.2753","article-title":"Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease.","volume":"85","author":"Ngo","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111816452111600_B50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1977.tb08812.x","article-title":"Heterogeneity of von Willebrand\u2019s disease: study of 40 Iranian cases.","volume":"37","author":"Shoa\u2019i","year":"1977","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111816452111600_B51","first-page":"826","article-title":"An inhibitor in the Willebrand-J\u00fcrgens syndrome and its effect on the factor VIII molecule properties [in German].","volume":"105","author":"Lenk","year":"1978","journal-title":"Folia Haematol (Frankf)"},{"issue":"3","key":"2019111816452111600_B52","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V75.3.654.654","article-title":"Severe type III von Willebrand\u2019s disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual.","volume":"75","author":"Peake","year":"1990","journal-title":"Blood"},{"issue":"2","key":"2019111816452111600_B53","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0038-1648835","article-title":"Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors.","volume":"72","author":"Mancuso","year":"1994","journal-title":"Thromb Haemost"},{"issue":"34","key":"2019111816452111600_B54","article-title":"Characteristics of inhibitors in severe von Willebrand\u2019s disease.","volume":"50","author":"Miller","year":"1983","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111816452111600_B55","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1046\/j.1365-2141.2000.02507.x","article-title":"Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease.","volume":"111","author":"Lak","year":"2000","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/5\/636\/1373919\/636.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/5\/636\/1373919\/636.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T21:46:00Z","timestamp":1574113560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/122\/5\/636\/32060\/Alloantibodies-in-von-Willebrand-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-10-462085","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,1]]}}}